Buscar en
Enfermedades Infecciosas y Microbiología Clínica (English Edition)
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica (English Edition) Dalbavancin treatment of prosthetic knee infection due to oxacillin-resistant St...
Journal Information
Vol. 36. Issue 2.
Pages 142-143 (February 2018)
Vol. 36. Issue 2.
Pages 142-143 (February 2018)
Scientific letter
Full text access
Dalbavancin treatment of prosthetic knee infection due to oxacillin-resistant Staphylococcus epidermidis
Tratamiento con dalbavancina de infección protésica de rodilla por Staphylococcus epidermidis resistente a la oxacilina
Visits
1936
María Ramírez Hidalgoa,
Corresponding author
ferchita@gmail.com

Corresponding author.
, Alfredo Jover-Sáenza, Mercè García-Gonzálezb, Fernando Barcenilla-Gaitea
a Unidad Funcional de Infecciones Nosocomiales, Hospital Universitari Arnau de Vilanova, Lleida, Spain
b Departamento de Microbiología, Hospital Universitari Arnau de Vilanova, Lleida, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

Infections associated with prosthetic joints are a serious health problem which require multi-disciplinary surgical and medical management. The situation may be complex in the case of allergy, resistance or contraindications to commonly used antibiotics if there are no alternatives. Dalbavancin may be an option but up until now no cases of prosthetic infection treated with this antibiotic have been published, according to the PubMed (years 2000–2017) database with key search words of: dalbavancin and prosthesis. A late reported case of prosthetic infection caused by Staphylococcus epidermidis and treated with dalbavancin is described.

We report the case of a woman aged 55 with a history of chronic kidney disease, short bowel syndrome, the carrier of a central venous catheter for total parenteral long-term nutrition and who had a knee arthroplasty in 2009. After 7 years she presented with signs of prosthetic knee infection. Complete removal of the prosthetic knee and the implantation of a spacer impregnated with vancomycin and gentamicin was carried out. In the samples obtained during the procedure S. epidermidis was isolated, with the minimum inhibitory concentration (MIC) for each antibiotic as described below: vancomycin sensitive (MIC1), daptomycin (MIC0.5) and linezolid (MIC1); resistant to cotrimoxazol (MIC>2/38), clindamycin (MIC>2), oxacillin (MIC>4) and levofloxacin (MIC>4). Due to the chronic kidney disease, we believed it correct not to use vancomycin, and a treatment with daptomycin in monotherapy was selected for 10 days. When the moment for sequential therapy was reached, the oral alternative with elevated bioavailability was linezolid, which was not used as its complete absorption could not be ensured due to the short bowel syndrome. In order to protect the catheter required for parenteral nutrition and avoid a prolonged hospital stay, outpatient treatment with dalbavancin was administered when its sensitivity by ETEST® (MIC0.047) was made known and in accordance with the recommendations from the Spanish Medicine Agency.1 A first dose of 1000mg iv was administered followed by a weekly dose of 500mg iv for 3 weeks. Two months after becoming asymptomatic and with no signs of infection or organ failure, reimplantation was carried out with continuation of empirical antibiotic treatment until negative obtainment of a total of 5 intraoperative cultures was made from the bone-prosthesis interphase, spacer and synovial fluid. Nine months after follow-up the patient continues in complete remission.

Infection associated with prostheses is one of the most serious complications of arthroplasty. The estimated rate of infection for knee arthoplasties in our environment is between 2% and 3%, with the staphylococcus bacteria being responsible for around 65% of cases.2,3 Combined therapy based on the extraction of prosthetic material, together with antimicrobial treatment obtains healing rates of around 80%.4 Dalbavancin is a parenteral antibiotic of the lipoglycopeptide group, with good action and penetrability in tissue compartments and demonstrates good bacterial activity compared with the majority of gram positive organisms.5 The susceptibility of dalbavancin compared with negative coagulase staphylococcus is around 100%.6 Dalbavancin has been assessed in vitro, with acceptable results in biofilms generated by staphylococcal infections, although there not enough evidence with regard to prosthetic joint material.7,8

In our case, with regard to dosing, the recognised recommendations used for treatment of acute skin and soft tissue infection in adult patients were used. This is the only indication which has been approved up until now.9 Unlike other antimicrobials where association with rifampicin has proven to be effective, its use in combined therapy does not appear to have been confirmed by the available scientific data which has supported it up until now, and for this reason monotherapy was chosen as therapy.7

To conclude, and as a result of this experience, dalbavancin could be used as an alternative in the treatment of oseoarticular infections caused by gram positive bacteria in the event of no other efficacious antimicrobial alternatives existing.

References
[1]
Informe de Posicionamiento Terapéutico de dalbavancina (Xydalba®). Ministerio de Sanidad, Servicios Sociales e Igualdad; Agencia Española de Medicamentos y Productos Sanitarios.
(2016),
Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IIPT-dalbavancina-Xydalba.pdf [accessed 19.04.17]
[2]
F. Jaén, M.I. Sanz-Gallardo, M.P. Arrazola, A. García de Codes, A. de Juanes, C. Resines, et al.
Multicentre study of infection incidence in knee prosthesis.
Rev Esp Cir Ortop Traumatol, 56 (2012), pp. 38-45
[3]
N. Benito, M. Franco, A. Ribera, A. Soriano, D. Rodriguez-Pardo, L. Sorlí, et al.
Time trends in the aetiology of prosthetic joint infections: a multicentre cohort study.
Clin Microbiol Infect, 22 (2016), pp. 732.e1-732.e8
[4]
J. Ariza, J. Cobo, J. Baraia-Etxaburu, N. Benito, G. Bori, J. Cabo, et al.
Management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).
(2016),
Available from: http://www.seimc.org/contenidos/gruposdeestudio/geio/dcientificos/documentos/geio-dc-2017-Guia_IPAS_EIMC.pdf [accessed 19.04.17]
[5]
J.J. Juul, C.F. Mullins, W.J. Peppard, A.M. Huang.
New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin.
Ther Clin Risk Manage, 12 (2016), pp. 225-232
[6]
M.D. Huband, M. Castanheira, D.J. Farrell, R.K. Flamm, R.N. Jones, H.S. Sader, et al.
In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011–2013).
Int J Antimicrob Agents, 47 (2016), pp. 495-499
[7]
D. Rodríguez-Pardo.
Evaluación de la evidencia clínica con dalbavancina.
Enferm Infecc Microbiol Clin, 35 (2017), pp. 33-37
[8]
D. Knafl, S. Tobudic, S.C. Cheng, D.R. Bellamy, F. Thalhammer.
Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE).
Eur J Clin Microbiol Infect Dis, 36 (2017), pp. 677-680
[9]
H.W. Boucher, M. Wilcox, G.H. Talbot, S. Puttagunta, A.F. Das, M.W. Dunne.
Once-weekly dalbavancin versus daily conventional therapy for skin infection.
N Engl J Med, 370 (2014), pp. 2169-2179

Please cite this article as: Ramírez Hidalgo M, Jover-Sáenz A, García-González M, Barcenilla-Gaite F. Tratamiento con dalbavancina de infección protésica de rodilla por Staphylococcus epidermidis resistente a la oxacilina. Enferm Infecc Microbiol Clin. 2018;36:142–143.

Copyright © 2017. Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos